Volumen 18 número 1 - Abril 2021
ISSN 0718-0918
Tabla de Contenidos > Trabajo Original
LETALIDAD EN LACTANTES CON CARDIOPATÍAS CONGÉNITAS HOSPITALIZADOS POR VIRUS RESPIRATORIO SINCICIAL
Leiva B. Felipe.1 , Elberg L. Mariana.1 , Palomino M. María Angélica.2
1 Facultad de Medicina, Universidad de Chile, Becado Hospital de Niños Dr. Roberto del Río
2 Facultad de Medicina, Universidad de Chile, Jefe Programa Especialización Pediatría, Pediatra Broncopulmonar, Profesor Titular de Pediatría, Hospital de Niños Dr. Roberto del Río

Resumen | Summary | Texto completo HTML | Descargar cuerpo en pdf

Introduction. Congenital heart disease is a risk factor for developing severe disease due to respiratory syncytial virus (RSV). In Chile the rate of hospitalization or lethality due to this cause is not known. The objective of this study was to determine lethality of infants with congenital heart disease hospitalized for RSV infection.

Method. Retrospective descriptive study, through review of clinical records of infants under 24 months with congenital heart disease, hospitalized due to low RSV respiratory infection. We recorded age, gender, type of congenital heart disease, comorbidities, days of hospitalization, admission to a critical patient unit and lethality in Roberto del Río Hospital between 2014 to 2016. The research had approved bay the ethical Comitee Servicio de Salud Metropolitano Norte. Results were analyzed through Stata 13.

Results. 94 hospitalized patients were studied, median age of 7.3 months, 45 (48%) men. The cases of congenital cyanotic heart disease were 7 (7.4%), left obstructive 3 (3.2%) and non-obstructive 84 (89.3%). The comorbidities were: 17 (18.08%) trisomy 21, 10 (10.6%) neurological pathology, 6 (6.38%) gastroesophageal reflux and 48 patients (51.06%) did not present. The hospitalization median is 8 days and the need for 1-day mechanical ventilation is greater in cyanotic patients. They require admission to the critical patient unit 49 (52.12%). The lethality is 8.5%.

Conclusion: The lethality of RSV infection observed in patients with congenital heart disease is high. In 2019 Chile implemented the use of RSV monoclonal antibodies congenital heart disease. New studies are needed to measure the impact of this new policy.
Keywords: congenital heart disease, respiratory syncytial virus

Revista Pediatría Electrónica
Zañartu 1085, Independencia, Santiago, Chile
Teléfonos:(56) 25758092 y 27354991
Correo electrónico: gmedina.uchile@gmail.com
ISSN 0718-0918